Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 May 9;37(18):e134.
doi: 10.3346/jkms.2022.37.e134.

Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study

Si-Ho Kim #  1 , Jin Yeong Hong #  2 , Seongman Bae #  3 , Hojin Lee #  4 , Yu Mi Wi  1 , Jae-Hoon Ko  2 , Bomi Kim  5 , Eun-Jeong Joo  5 , Hyeri Seok  6 , Hye Jin Shi  7 , Jeong Rae Yoo  8 , Miri Hyun  9 , Hyun Ah Kim  9 , Sukbin Jang  10 , Seok Jun Mun  11 , Jungok Kim  12 , Min-Chul Kim  13 , Dong-Sik Jung  14 , Sung-Han Kim  15 , Kyong Ran Peck  16
Affiliations
Multicenter Study

Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study

Si-Ho Kim et al. J Korean Med Sci. .

Abstract

Background: Coronavirus disease 2019 (COVID-19) is often accompanied by secondary infections, such as invasive aspergillosis. In this study, risk factors for developing COVID-19-associated pulmonary aspergillosis (CAPA) and their clinical outcomes were evaluated.

Methods: This multicenter retrospective cohort study included critically ill COVID-19 patients from July 2020 through March 2021. Critically ill patients were defined as patients requiring high-flow respiratory support or mechanical ventilation. CAPA was defined based on the 2020 European Confederation of Medical Mycology and the International Society for Human and Animal Mycology consensus criteria. Factors associated with CAPA were analyzed, and their clinical outcomes were adjusted by a propensity score-matched model.

Results: Among 187 eligible patients, 17 (9.1%) developed CAPA, which is equal to 33.10 per 10,000 patient-days. Sixteen patients received voriconazole-based antifungal treatment. In addition, 82.4% and 53.5% of patients with CAPA and without CAPA, respectively, received early high-dose corticosteroids (P = 0.022). In multivariable analysis, initial 10-day cumulative steroid dose > 60 mg of dexamethasone or dexamethasone equivalent dose) (adjusted odds ratio [OR], 3.77; 95% confidence interval [CI], 1.03-13.79) and chronic pulmonary disease (adjusted OR, 4.20; 95% CI, 1.26-14.02) were independently associated with CAPA. Tendencies of higher 90-day overall mortality (54.3% vs. 35.2%, P = 0.346) and lower respiratory support-free rate were observed in patients with CAPA (76.3% vs. 54.9%, P = 0.089).

Conclusion: Our study showed that the dose of corticosteroid use might be a risk factor for CAPA development and the possibility of CAPA contributing to adverse outcomes in critically ill COVID-19 patients.

Keywords: Aspergillosis; COVID-19; SARS-CoV-2; Steroid.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Study population.
COVID-19 = coronavirus disease 2019, CAPA = COVID-19-associated pulmonary aspergillosis.
Fig. 2
Fig. 2. Cumulative incidence curve of primary and secondary outcomes. (A) 90-day overall mortality (raw data), (B) 90-day overall mortality (propensity score [PS]-matched model), (C) respiratory support-free rates among surviving patients (raw data), and (D) respiratory support-free rates among surviving patients (PS-matched model).
CAPA = COVID-19-associated pulmonary aspergillosis.
See this image and copyright information in PMC

References

    1. World Health Organization. WHO coronavirus (COVID-19) dashboard. [Updated 2022]. [Accessed March 12, 2022]. https://covid19.who.int/
    1. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032. - PMC - PubMed
    1. Koehler P, Bassetti M, Chakrabarti A, Chen SC, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149–e162. - PMC - PubMed
    1. Heard KL, Hughes S, Mughal N, Moore LS. COVID-19 and fungal superinfection. Lancet Microbe. 2020;1(3):e107. - PMC - PubMed
    1. Schauwvlieghe AF, Rijnders BJ, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–792. - PubMed

Publication types

MeSH terms